135 related articles for article (PubMed ID: 10498878)
21. Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic leukemia.
Liu W; Zhu YS; Guo M; Yu Y; Chen GQ
Leuk Res; 2007 Nov; 31(11):1565-74. PubMed ID: 17428537
[TBL] [Abstract][Full Text] [Related]
22. Complications of therapy in cancer patients: Case 2. Scrotal ulceration during all-trans-retinoic acid therapy for acute promyelocytic leukemia.
Gettinger S; Shapira I; Scheinfeld N; Grossbard M
J Clin Oncol; 2004 Nov; 22(22):4648-9. PubMed ID: 15542816
[No Abstract] [Full Text] [Related]
23. Pharmacokinetics of all-trans retinoic acid in adults and children with acute promyelocytic leukemia.
Takitani K; Koh M; Inoue A; Kawakami C; Kuno T; Tamai H
Am J Hematol; 2006 Sep; 81(9):720-1. PubMed ID: 16838336
[No Abstract] [Full Text] [Related]
24. Diagnosis, front line treatment and molecular monitoring of acute promyelocytic leukaemia.
Lo Coco F; Diverio D; Avvisati G; Mandelli F
Haematologica; 1999 Jun; 84 Suppl EHA-4():72-4. PubMed ID: 10907474
[No Abstract] [Full Text] [Related]
25. All-trans-retinoic acid-induced myositis in a child with acute promyelocytic leukemia.
Citak FE; Ezer U; Akkaya E; Ozbulbul N; Bahce M; Kurekci AE
Haematologica; 2006 Aug; 91(8 Suppl):ECR35. PubMed ID: 16923519
[TBL] [Abstract][Full Text] [Related]
26. Significance of persistent Auer rods and cytogenetic abnormality after first cycle of therapy for acute promyelocytic leukaemia.
Dalal BI; Bruyere H; Barnett MJ
Br J Haematol; 2007 Jun; 137(5):385. PubMed ID: 17374141
[No Abstract] [Full Text] [Related]
27. [Arsenic efficient in acute promyelocytic leukemia].
Lehmann S; Paul C
Lakartidningen; 1999 Dec; 96(50):5626-8. PubMed ID: 10643228
[TBL] [Abstract][Full Text] [Related]
28. Differentiation therapy for acute promyelocytic leukemia with all-trans retinoic acid: 10-year experience of its clinical application.
Wang Z; Sun G; Shen Z; Chen S; Chen Z
Chin Med J (Engl); 1999 Nov; 112(11):963-7. PubMed ID: 11721474
[TBL] [Abstract][Full Text] [Related]
29. Acute promyelocytic leukemia--molecular breakthrough.
Ross DW
Arch Pathol Lab Med; 1991 Aug; 115(8):845. PubMed ID: 1863199
[No Abstract] [Full Text] [Related]
30. Reversible cardiac dysfunction without myocytolysis related to all-trans retinoic acid administration during induction therapy of acute promyelocytic leukemia.
Manna A; Cadenotti L; Motto A; Ballo P
Ann Hematol; 2009 Jan; 88(1):91-2. PubMed ID: 18633613
[No Abstract] [Full Text] [Related]
31. Interferon enhanced minimal residual disease detection in acute promyelocytic leukaemia.
Palumbo GA; Romeo MA; Di Raimondo F; Giustolisi R
Br J Haematol; 1997 Mar; 96(4):876-7. PubMed ID: 9074438
[No Abstract] [Full Text] [Related]
32. [Pathogenesis of acute promyelocytic leukemia].
Tokuhira M; Kizaki M
Nihon Rinsho; 2012 Apr; 70 Suppl 2():409-14. PubMed ID: 23133991
[No Abstract] [Full Text] [Related]
33. Acute promyelocytic leukemia (AML-M3)--Part 2: Molecular defect, DNA diagnosis, and proposed models of leukemogenesis and differentiation therapy.
Randolph TR
Clin Lab Sci; 2000; 13(2):106-16. PubMed ID: 11066449
[TBL] [Abstract][Full Text] [Related]
34. A case of acute promyelocytic leukemia showing transient thrombocytosis caused by increased interleukin-6 and thrombopoietin after treatment with all-trans retinoic acid and chemotherapy.
Kondo M; Nakabayashi Y; Sugiyama A; Tominaga T; Shinohara K
Gan To Kagaku Ryoho; 2009 May; 36(5):827-30. PubMed ID: 19461187
[TBL] [Abstract][Full Text] [Related]
35. Extramedullary relapse in acute promyelocytic leukemia.
Pagano L; Sica S; Marra R; Storti S; Leone G
Leuk Lymphoma; 1997 Jul; 26(3-4):417-8. PubMed ID: 9322908
[No Abstract] [Full Text] [Related]
36. TRAIL leads to apoptosis in acute promyelocytic leukaemia.
Bradbury J
Lancet; 2001 Jun; 357(9270):1770. PubMed ID: 11403822
[No Abstract] [Full Text] [Related]
37. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Ma J
Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
[No Abstract] [Full Text] [Related]
38. [Advances in medical genetics].
Wu M
Zhonghua Yi Xue Za Zhi; 1993 Dec; 73(12):748-9. PubMed ID: 8143192
[No Abstract] [Full Text] [Related]
39. Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute promyelocytic leukemia.
Yin CC; Glassman AB; Lin P; Valbuena JR; Jones D; Luthra R; Medeiros LJ
Am J Clin Pathol; 2005 Jun; 123(6):840-8. PubMed ID: 15899774
[TBL] [Abstract][Full Text] [Related]
40. [Therapy-related acute promyelocytic leukemia with a t(9;22)(q34;q11) and t(15;17)(q22;q11 to approximately 12) subclone].
Mochiduki Y; Muramoto S
Rinsho Ketsueki; 2005 Nov; 46(11):1218-22. PubMed ID: 16440807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
